Filtered By:
Source: Neurology
Drug: Coumadin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 64 results found since Jan 2013.
Treatment Patterns and Outcomes of Patients Receiving Direct Oral Anticoagulants or Low Molecular Weight Heparin who Experienced Life-threatening Intracranial Hemorrhage (P5.053)
Conclusions:This study provides a real-world picture of patients receiving FXa inhibitors or LMWH, experiencing life-threatening intracranial bleeds. Despite efforts to restore hemostasis, mortality remained high and substantial healthcare resources were expended. This highlights the need to develop specific strategies for management of ICH in this patient population.Study Supported by: Portola Pharmaceuticals, Inc.Disclosure: Dr. Milling has received personal compensation for activities with CSI Behring, Janssen, BI, and Portola. Dr. Feronti has received research support from Portola. Dr. Clark has received research perso...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Milling, T. J., Feronti, C., Clark, C. L., Fermann, G. J., Song, S. S., Torbati, S. S., Weiss, J., Patel, D., Neuman, W. R. Tags: Neurocritical Care: Intracerebral Hemorrhage Source Type: research
Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients (S51.001)
Conclusions:Among NVAF patients with a prior history of SSE, rivaroxaban reduced ischemic stroke and ICH risk versus warfarin and did not significantly impact major bleeding. Apixaban did not significantly alter patients’ risk of SSE or major bleeding compared to warfarin in this high-risk population.Study Supported by: Bayer Pharma AGDisclosure: Dr. Coleman has received personal compensation for activities with Janssen Scientific affairs, LLC, Bayer Pharma AG, and BIPI . Dr. Coleman has received research support from Janssen Scientific Affairs, LLC, and Bayer Pharma AG. Dr. Bunz has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Coleman, C., Bunz, T. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research
Resumption of Antithrombotic Therapy in LVAD-associated Intracranial Hemorrhages (P2.273)
Conclusions:Among survivors of LVAD-associated ICH, those who resumed both antiplatelet plus warfarin therapy had fewer ischemic, but more hemorrhagic events than those who resumed antiplatelet therapy alone.Disclosure: Dr. Cho has nothing to disclose. Dr. Frontera has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cho, S.-M., Frontera, J. Tags: Intracerebral Hemorrhage Source Type: research
Using Artificial Intelligence to Reduce Risk of Non-Adherence in Patients on Anticoagulation Therapy (S53.002)
Conclusions:Elderly stroke patients, many with little experience using a smartphone, successfully used an AI application to monitor and increase adherence to anticoagulation therapy over 12 weeks. Patients monitored by the AI Platform demonstrated a 50% absolute improvement in adherence based on plasma drug levels. Continuous monitoring has the potential to increase adherence, change patient behavior and reduce the risks associated with non-adherence, particularly in patients on DOAC therapy.Study Supported by:AcknowledgmentFunding was received from the National Center for Advancing Translational Sciences (NCATS), grant nu...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Labovitz, D., Shafner, L., Virmani, D., Hanina, A. Tags: General Neurology: Mechanisms and Diagnosis in Overlapping Medical and Neurological Diseases Source Type: research
Safety of OnabotulinumtoxinA Treatment With Concomitant Antithrombotic Therapy in Patients With Post-stroke Spasticity: A Pooled Analysis of Randomized, Double-Blind Studies (S56.008)
Conclusions:There is no apparent increased risk of bleeding complications in patients on antithrombotics following IM onabotA treatment; nonetheless, careful observation of the injection site and patient education of the potential for bleeding complications remain warranted.Study Supported by: Allergan plc, Dublin, IrelandDisclosure: Dr. Dimitrova has received personal compensation for activities with Allergan as an employee. Dr. Dimitrova holds stock and/or stock options in Allergan. Dr. James has received personal compensation for activities with Allergan and Chase Pharmaceuticals as an employee. Dr. Liu has received per...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Dimitrova, R., James, L., Liu, C., Orejudos, A., Yushmanova, I., Brin, M. Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research
Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage (P4.271)
Conclusions:These data suggest that IV rt-PA can be safely administered in coagulopathic and thrombocytopenic patients. Although rates of sICH and mortality were similar to the NINDS cohort, caution may be needed to identify certain hemorrhagic risk factors. Routine exclusion of anticoagulated or thrombocytopenic patients is not supported and the use of IV rt-PA in these patients may increase the eligibility for acute stroke therapy, particularly at institutions where IA therapy is unavailable.Disclosure: Dr. Barazangi has received personal compensation for activities with Genentech. Dr. Sorensen has nothing to disclose. D...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Barazangi, N., Sorensen, S., Chen, C., Wong, C., Yee, A., Ke, M., Rose, J., Grosvenor, D., Bedenk, A., Fernandes, J., Tong, D. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research
Hemorrhagic transformation of ischemic strokes: risk factors and prognostic implications (P4.291)
Conclusions:IV thrombolytic therapy, cardioembolic stroke and prior warfarin use were independent predictors of HT. PH2 was associated with increased risk of poor outcome at around 90 days and mortality at 90 days and 5 years.Disclosure: Dr. Cheung has nothing to disclose. Dr. Chan has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cheung, R., Chan, K. H., Lee, R. Tags: In-Hospital Stroke Care Source Type: research
Analysis of current clinical practice on initiation of anticoagulation in patients with acute ischemic stroke. (P4.298)
Conclusions:Physicians with a subspecialty in vascular neurology, those with more years of experience in practice, and those practicing at academic institutions tended to initiate anticoagulation later.Disclosure: Dr. Olivas has nothing to disclose. Dr. Ajani has nothing to disclose. Dr. Yao has nothing to disclose. Dr. Sangha has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Olivas, E., Ajani, Z., Yao, J., Sangha, N. Tags: In-Hospital Stroke Care Source Type: research
A rare cause of stroke in young: PHACE syndrome (P1.253)
Conclusions:Neurocutaneous syndromes are typically diagnosed in childhood and can be a rare cause of stroke in young. Our patient suffered an ischemic stroke secondary to sequelae of undiagnosed PHACE syndrome. Early identification of neurocutaneous syndromes allows for proper surveillance, evaluation, and preventative education for development of complications.Disclosure: Dr. Fitzgerald has nothing to disclose. Dr. Chandra has nothing to disclose. Dr. Dannenbaum has nothing to disclose. Dr. Sharrief has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Fitzgerald, K., Chandra, S., Dannenbaum, M., Sharrief, A. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
Difference of Clinical Condition of Ischemic Stroke between Warfarin and Direct Oral Anticoagulants (P6.285)
Conclusions:Ischemic lesion size may be smaller in DOACs compared with warfarin. There is a possibility that direct thrombin inhibitor may provide better outcome compared with other anticoagulants. Larger prospective study should be conducted to confirm these findings.Disclosure: Dr. Nakase has nothing to disclose. Dr. Moroi has nothing to disclose. Dr. Ishikawa has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Nakase, T., Moroi, J., Ishikawa, T. Tags: Prevention of Cerebrovascular Disease Source Type: research
Rates of Adverse Events in the Very Old: A Community Anticoagulation Clinic Study (P6.291)
Conclusions:The very old still achieve minimum TTR to experience anticoagulation benefits. Patients older than 95 are at appreciably increased risk of hemorrhage, while ischemic events were overrepresented in ages 90–95. Future work aims to determine risk factors for thrombotic and hemorrhagic events in the very old.Disclosure: Dr. Stanley has nothing to disclose. Dr. Knight has nothing to disclose. Dr. Stein has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Stanley, M., Knight, C., Stein, R. Tags: Prevention of Cerebrovascular Disease Source Type: research
Rare Cases of Thrombotic and Embolic Stroke with Hypereosinophilia (P1.295)
Conclusions:Hypereosinophilia can cause both embolic and thrombotic strokes as evidenced by our patients. The etiology of embolic stroke may be due to the direct eosinophilic damage to the endocardium or by the release of eosinophilic basic proteins which initiate endomyocardial necrosis, making the heart a potential source of emboli. Causes of thrombogenicity are multifactorial including the release of tissue factor from specific granules, inactivation of thrombomodulin by binding to the major basic protein, endothelial damage or by elevation of fibrinogen levels. The individual presentations (thrombotic/embolic) will alt...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Finelli, D., Shoamanesh, A., Perera, K. Tags: Cerebrovascular Disease Case Reports I Source Type: research
Cor Triatriatum and Stroke: A Case Report and Review of Literature (P3.294)
Conclusions:This is the largest review of CTS cases with associated stroke. The review showed neuroimaging results consistent with a cardioembolic mechanism. All but two of the cases made use of anticoagulation. Three cases underwent surgery. This case has the longest follow-up and the first to demonstrate failure of anti-platelet therapy and anticoagulation. The need for further investigations regarding optimal stroke prevention in this subset of patients is emphasized.Disclosure: Dr. Diestro has nothing to disclose. Dr. Espiritu has nothing to disclose. Dr. Dorotan has nothing to disclose. Dr. Regalado has nothing to dis...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Diestro, J. D., Espiritu, A., Dorotan, M. K., Regalado, J., Pascual, J. L. Tags: Cerebrovascular Disease Case Reports II Source Type: research
Diffusion Weighted Imaging in a Case of Longitudinally Extensive Transverse Myelitis in Neuromyelitis Optica (P6.395)
Conclusions:Limited data exist on DWI and ADC patterns in demyelinating disease, particularly for NMO and LETM. Understanding these neuroimaging patterns in patients who cannot receive gadolinium is important in diagnosing NMO and providing prompt treatment.Disclosure: Dr. Gluck has nothing to disclose. Dr. Vollbracht has received personal compensation for activities with Teva as a speaker.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Gluck, L., Vollbracht, S. Tags: Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, and Optic Neuritis B Source Type: research
Recurrent cryptogenic stroke in young adult linked to congenital left ventricular diverticulum
A 47-year-old man had an acute ischemic stroke (IS); brain MRI revealed multiple silent old IS (figure 1A). A comprehensive workup, including prolonged cardiac monitoring (cumulated duration of 25 days) and cardiac transthoracic/transesophageal echography, was negative. Eleven months later, despite statin and aspirin therapy, a new symptomatic embolic IS of undetermined source occurred (figure 1B). Cardiac MRI1 revealed a left apical dyskinetic saccular evagination (figure 2, A–C) consistent with a congenital left ventricular diverticulum confirmed on left ventriculography (figure 2D) and the presumed source of recur...
Source: Neurology - November 13, 2016 Category: Neurology Authors: Gaillard, N., Targosz, F., Bertrand, J. L., Sablot, D., Bensalah, Z. M. Tags: Stroke in young adults, Cardiac, Embolism, Infarction NEUROIMAGES Source Type: research
